Ozempic Lawsuit | 2026 Latest Updates

Lawsuits allege that Ozempic, the semaglutide drug made by Novo Nordisk, caused gastroparesis, often called stomach paralysis, and other digestive injuries. Separate cases allege that Ozempic caused NAION, a form of vision loss.

The U.S. cases are generally personal injury actions. They are centralized in MDL 3094 in the Eastern District of Pennsylvania before Judge Karen S. Marston. The vision-loss cases sit in a second MDL, number 3163, before the same judge.

Novo Nordisk and Eli Lilly deny the allegations, which say the makers failed to warn about these risks. A hearing on expert evidence was scheduled for September 2026. No settlement or verdict has been announced.

Latest Ozempic Lawsuit Updates

September 14, 2026: Judge Marston Sets Rule 702 Hearing

Judge Karen S. Marston of the Eastern District of Pennsylvania set a Rule 702 (“Daubert”) evidentiary hearing in MDL 3094 for September 14, 2026 through September 18, 2026, the court’s MDL 3094 page says [1].

The hearing covers Cross Cutting Issues 2 and 3. The MDL hears personal injury actions over drugs including Ozempic, Wegovy and Rybelsus, made by Novo Nordisk.

September 1, 2026: JPML Reports Pending Case Counts

The Judicial Panel on Multidistrict Litigation (JPML) lists 4,185 pending actions in MDL 3094 and 153 in MDL 3163 in its September 1, 2026 report [2].

February 5, 2026: MHRA Publishes NAION Safety Update

The UK Medicines and Healthcare products Regulatory Agency (MHRA) published a Drug Safety Update [3]. The MHRA Drug Safety Update says NAION has been very rarely reported with Ozempic, Wegovy and Rybelsus.

The update says a sudden loss of vision should be urgently referred for eye examination. It adds that a report to the MHRA does not mean a case was definitely linked to the medicine.

December 16, 2025: Court Resets Expert Evidence Deadlines

Judge Marston’s Case Management Order No. 29 reset the MDL 3094 deadlines for Cross Cutting Issues 2 and 3 [4]. It replaced the earlier schedule for those two issues.

Motions to exclude expert opinions under Rule 702 were due April 28, 2026. Summary judgment motions on those issues were due April 30, 2026.

December 15, 2025: JPML Creates NAION MDL 3163

The Panel’s December 15, 2025 order created MDL 3163 for NAION cases [5]. It assigned the cases to Judge Marston. 21 actions were pending in three districts.

Eli Lilly had asked the Panel to centralize the NAION cases. The Panel agreed but declined to fold them into MDL 3094. It was also notified of nine related actions.

August 15, 2025: Judge Rules on Gastric Emptying Studies

Judge Marston ruled on August 15, 2025 that any plaintiff claiming drug-induced gastroparesis must have had a properly performed gastric emptying study at diagnosis [6].

The court granted the defendants’ motions to exclude the opinions of plaintiffs’ experts Drs. Raines and Siegel. The ruling concerns how gastroparesis is diagnosed, not whether the drugs cause it.

August 13, 2025: Two JAMA Studies Reach Different NAION Results

Fox News reported on two JAMA studies of popular weight loss drugs and eye conditions in people with type 2 diabetes [7]. One counted 35 NAION cases against 19 in a comparison group among more than 159,000 participants.

The second study did not observe a statistically significant difference in NAION. An outside physician told Fox that NAION has not really been shown to be increased by these studies.

June 6, 2025: EMA Committee Calls NAION a Very Rare Side Effect

The European Medicines Agency (EMA) safety committee, PRAC, concluded that NAION is a very rare side effect of semaglutide medicines including Ozempic [8]. Very rare means it may affect up to 1 in 10,000 people taking semaglutide.

PRAC said patients with sudden loss of vision should contact their doctor without delay. If NAION is confirmed, treatment with semaglutide should be stopped.

November 4, 2024: TIME Reports on Patient Lawsuits

TIME reported that thousands of people have filed, or are expected to file, lawsuits against Novo Nordisk and Eli Lilly [9]. The article describes people with intestinal blockages, gallbladder damage and especially gastroparesis after taking GLP-1 drugs.

In the article, Novo Nordisk called the lawsuits “without merit,” and Eli Lilly said it will “vigorously defend against these claims.”

August 1, 2024: JAMA Ophthalmology Study Reports NAION Association

The Hathaway study, a Harvard-affiliated study in JAMA Ophthalmology, focused on patients with type 2 diabetes [10]. It reported 17 NAION events among 194 patients prescribed semaglutide. Among 516 patients on other diabetes drugs, it reported 6.

The authors wrote that the findings suggest an association between semaglutide and NAION. They noted that, as an observational study, future study is required to assess causality.

March 21, 2024: USA TODAY Reports on Federal Cases

USA TODAY reported that more than five dozen lawsuits target Novo Nordisk or Eli Lilly [11]. They accuse the makers of failing to warn about side effects of Ozempic and other drugs.

The report said a federal judge in Philadelphia was handling the personal injury lawsuits together. Eli Lilly’s Mounjaro and Trulicity are also named.

November 2, 2023: Proposed Class Action Filed in British Columbia

CTV News Vancouver reported that a proposed class action lawsuit was filed in British Columbia against the Canadian maker of the weight loss drug Ozempic [12]. The suit alleges the manufacturer did not warn patients about possible complications.

August 2, 2023: Jaclyn Bjorklund Files Lawsuit

HealthDay reported that Jaclyn Bjorklund, 44, of Louisiana sued Novo Nordisk and Eli Lilly [13]. She alleges they failed to adequately warn about the risk of severe stomach problems from Ozempic and Mounjaro.

Her attorney filed the lawsuit on Wednesday and said she is suffering persistent vomiting and severe gastroparesis. A Novo Nordisk spokeswoman said the company was unaware of the lawsuit.

What Is Gastroparesis?

Gastroparesis, or delayed gastric emptying, slows or stops food moving from the stomach to the small intestine, says the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [14].

NIDDK says the stomach muscles work poorly or not at all in this disorder, and the stomach takes too long to empty its contents.

Who May Be Affected?

The cases in MDL 3094 involve people prescribed Ozempic, Wegovy, Rybelsus or Saxenda who allege gastroparesis, ileus, intestinal obstruction or another digestive injury. The Panel’s December 12, 2024 order added Saxenda to the MDL [15].

Mounjaro and Trulicity, from Eli Lilly, are also in MDL 3094. The court notes that each plaintiff claims a prescription for type 2 diabetes, chronic weight management or both.

The gastric emptying study in the August 15, 2025 ruling can be scintigraphy, a breath test or a wireless motility capsule.

People who allege NAION vision loss after Ozempic, Wegovy, Saxenda or Trulicity have cases in MDL 3163 instead. That is the separate MDL for NAION cases before the same judge.

Wegovy and Ozempic both contain semaglutide. The Wegovy stomach paralysis lawsuit page covers the Wegovy cases. An individual legal review of your records can show whether your situation qualifies.

Reported Injuries or Damages

The August 15, 2025 ruling recounts what the master complaint alleges. The injuries include debilitating cyclical vomiting, gastroparesis, ileus and intestinal obstruction. Other alleged injuries are gallbladder injury, vitamin deficiency, Wernicke’s encephalopathy, ischemic bowel and necrotizing pancreatitis.

Plaintiffs’ counsel anticipated that over 95% of the cases will allege gastroparesis. A separate set of plaintiffs alleges the eye condition NAION.

In the Hathaway study, the 36-month NAION rate was 8.9% with semaglutide and 1.8% with other diabetes drugs. The EMA cited studies that suggest about a two-fold higher risk in adults with type 2 diabetes.

The FDA-approved Ozempic label says use has been associated with gastrointestinal adverse reactions, sometimes severe. It says Ozempic is not recommended in patients with severe gastroparesis [16].

Recall and Regulatory Background

The FDA-approved Ozempic label, revised in October 2025, lists ileus, intestinal obstruction and severe constipation including fecal impaction among reactions reported after approval.

The label says these reports are voluntary and come from a group of unknown size. So it cannot always show that the drug caused them.

Evidence to Preserve

Keep these records:

• Ozempic prescriptions and pharmacy and purchase records that show when you got the medicine.
• The pens and packaging, along with any labels or papers that came with them.
• A record of the dates you started, stopped and changed your dose of the medicine.
• Medical records and test results, including any gastric emptying study or eye exam results.
• Photos and a dated log of symptoms such as vomiting, with notes on how often they happen.
• Hospital and billing records for any care you got for stomach or vision symptoms.
• Messages with doctors or the maker of the medicine about your symptoms.

Filing Deadlines

State law sets the deadline to file an injury claim. The deadline depends on where you live, when the injury happened and when the diagnosis was made.

Missing the deadline can end a claim altogether, even when the facts of the injury are strong and well documented by medical records.

A lawyer can tell you which time limit applies to your own situation, so ask a lawyer promptly about your dates.

Frequently Asked Questions

Is There an Ozempic Class Action Lawsuit?

There is no Ozempic class action lawsuit in MDL 3094, which the court describes as generally personal injury actions. A proposed class action was filed in British Columbia against Ozempic’s Canadian maker. Case Management Order No. 27 says the master complaint is not intended to merge plaintiffs’ claims.

What Does the Research Say About Ozempic and Stomach Paralysis?

Research on Ozempic and stomach paralysis includes the FDA label, which reports severe gastrointestinal reactions in 0.4% of patients on 0.5 mg and 0.8% on 1 mg, against 0% on placebo. The label says Ozempic delays gastric emptying.

Is There an Ozempic Stomach Paralysis Lawsuit Settlement?

There is no Ozempic stomach paralysis lawsuit settlement so far. Neither MDL 3094 nor MDL 3163 has produced a settlement or verdict, and the cases in both MDLs remain in pretrial proceedings.

Is There a Lawsuit for Ozempic Vision Loss?

Yes, there are Ozempic vision loss lawsuits. MDL 3163 handles cases alleging NAION. Plaintiffs there bring claims for failure to warn, design defect and breach of warranties, and some also allege gastrointestinal injuries.

Do I Need a Gastric Emptying Study to Bring a Claim?

You may need a properly performed gastric emptying study to bring a gastroparesis claim. Plaintiffs’ counsel conceded one is necessary for the other subsets, and the court’s ruling also requires one for drug-induced gastroparesis. The court acknowledged some plaintiffs may be unable to prove gastroparesis without one.

Should I Stop Taking Ozempic?

Talk to your doctor before you stop taking Ozempic. Novo Nordisk has said it recommends patients take its medications for their approved indications and under the supervision of a health care professional.

References

1. https://www.paed.uscourts.gov/node/2669
2. https://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_Actions_Pending-September-1-2026.pdf
3. https://www.gov.uk/drug-safety-update/semaglutide-wegovy-ozempic-and-rybelsus-risk-of-non-arteritic-anterior-ischemic-optic-neuropathy-naion
4. https://www.paed.uscourts.gov/sites/paed/files/mdl-orders/24md3094_cm-ord_29.pdf
5. https://www.jpml.uscourts.gov/sites/jpml/files/MDL-3163-Transfer_Order-12-25.pdf
6. https://assets.alm.com/49/40/6783287f42c0938c3e0887e31822/opinion-on-issue-1-rule-702-motions-8-15-2025.pdf
7. https://www.foxnews.com/health/popular-weight-loss-drugs-linked-sudden-vision-loss-research-suggests
8. https://www.ema.europa.eu/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy
9. https://time.com/7130456/ozempic-side-effects-wegovy-mounjaro-gastroparesis-weight-loss/
10. https://pmc.ncbi.nlm.nih.gov/articles/PMC11223051/
11. https://www.usatoday.com/story/news/health/2024/03/21/lawsuits-ozempic-wegovy-weight-loss-drugs-diabetes-harmful/72947158007/
12. https://www.ctvnews.ca/vancouver/article/proposed-class-action-lawsuit-filed-against-canadian-maker-of-popular-weight-loss-drug-ozempic/
13. https://www.healthday.com/health-news/public-health/ozempic-2662691507.html
14. https://www.niddk.nih.gov/health-information/digestive-diseases/gastroparesis/definition-facts
15. https://www.jpml.uscourts.gov/sites/jpml/files/MDL-3094-Transfer_Order-12-24.pdf
16. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035,209637s037lbl.pdf